000172711 000__ 01463fam\a2200337\a\4500
000172711 001__ 172711
000172711 005__ 20220217103502.0
000172711 008__ 930331s1993\\\\dcu\\\\\\b\\\f000\0\eng\d
000172711 020__ $$a0160402093
000172711 035__ $$a(OCoLC)ocm27831597
000172711 035__ $$9(IS)TVT4443
000172711 035__ $$9AAU0569SI
000172711 035__ $$a172711
000172711 040__ $$aFTC$$cFTC$$dGPO
000172711 043__ $$an-us---
000172711 049__ $$aISUW
000172711 074__ $$a1016-A
000172711 0860_ $$aY 4.G 74/7:C 83/3
000172711 090__ $$aRS189$$b.U5H8 1992a
000172711 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Government Operations.$$bHuman Resources and Intergovernmental Relations Subcommittee.
000172711 24510 $$aCouncil on Competitiveness and FDA plans to alter the drug approval process at FDA :$$bhearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, second session, March 19, 1992.
000172711 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office,$$c1993.
000172711 300__ $$aiii, 357 p. ;$$c24 cm.
000172711 500__ $$aDistributed to some depository libraries in microfiche.
000172711 500__ $$aShipping list no.: 93-0181-P.
000172711 504__ $$aIncludes bibliographical references.
000172711 61020 $$aCouncil on Competitiveness (U.S.)
000172711 61010 $$aUnited States.$$bFood and Drug Administration.
000172711 650_0 $$aPharmaceutical policy$$zUnited States.
000172711 650_0 $$aDrugs$$zUnited States$$xTesting.
000172711 85230 $$bdfich$$hY 4.G 74/7:$$iC 83/3
000172711 909CO $$ooai:library.usi.edu:172711$$pGLOBAL_SET
000172711 948__ $$ac:jk
000172711 980__ $$aBIB
000172711 980__ $$aGOV RESOURCE